Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

BACKGROUND: Bevacizumab is associated with an increased risk of arterial thromboembolism (ATE), however, its effect on venous thromboembolism (VTE) remains controversial. Scant data exist on factors that increase ATE/VTE risk in prostate cancer patients. We investigated the association of bevacizuma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Patel, Jai N., Jiang, Chen, Hertz, Daniel L., Mulkey, Flora A., Owzar, Kouros, Halabi, Susan, Ratain, Mark J., Friedman, Paula N., Small, Eric J., Carducci, Michael A., Mahoney, John F., Kelley, Michael J., Morris, Michael J., Kelly, William K., McLeod, Howard L.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4368497/
https://ncbi.nlm.nih.gov/pubmed/25417775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29169
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares